ArticleBMC medical imaging2026
Multiparametric MRI approach identifies pathologic complete response in patients with local advanced rectal cancer after neoadjuvant therapy.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the value of magnetic resonance imaging (MRI) in identifying the pathologic complete response (pCR) of patients with locally advanced rectal cancer (LARC) after neoadjuvant therapy (NAT). MATERIALS AND
methodsThis retrospective study included 152 patients with LARC who underwent NAT followed by total mesorectal excision (TME) at our hospital between January 2019 and November 2024. The response to NAT was assessed using MRI. At first, the response was assessed according to MRI-based tumor regression grade (mrTRG), which was only on the basis of T2 weighted imaging (T2WI). Then, diffusion weighted imaging (DWI) was added to construct biparametric MRI-based tumor regression grade (BPmrTRG), followed by multiparametric MRI-based tumor regression grade (MPmrTRG) consisting of T2WI, DWI and contrast-enhanced T1-weighted imaging (CE-T1WI). The diagnostic efficacy of the three methods for identifying pCR was assessed by calculating the area under the receiver operating characteristic (ROC) curve (AUC), positive predictive value (PPV), negative predictive value (NPV), sensitivity, and specificity. The DeLong test was used to compare the AUCs of different methods.
resultsOf the 152 patients, 27 (17.8%) were obtained pCR at surgical histopathological analysis. Among the three different MRI-based TRG methods, MPmrTRG archived the highest AUC of 0.891 (95% CI: 0.814-0.957) to identify pCR after NAT, followed by an AUC of 0.840 (95%CI: 0.745-0.916) for BPmrTRG and 0.729 (95% CI: 0.630-0.818) for mrTRG. Paired comparisons showed that AUC of MPmrTRG was higher than that of mrTRG with statistically significant after Bonferroni correction (p = 0.007), as well as the sensitivity (0.815 vs. 0.481, p = 0.008).
conclusionAfter adding DWI and CE-T1WI, the multiparametric MRI approach could improve diagnosis performance for identifying pCR after NAT in patients with LARC, which could facility clinicians' decision and patients' consultation for the watch and wait strategy to forgo the surgery and preserve the organ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.